Lowenstein Sandler represented private equity firm Hildred Capital in connection with raising $750 million for its continuation fund to extend its ownership of two of its portfolio companies, Hyland’s Naturals and Crown Laboratories.

The funding permits Hildred to continue ownership of Crown Laboratories, which makes skin-care products, and Hyland’s Naturals, which makes natural vitamins and minerals and over-the-counter medications, particularly for children; it may also fund acquisitions by either or both of the companies.

Hildred Capital Management focuses on middle-market companies across the world of healthcare. Based in New York, Hildred began in 2014 as a family office and in 2019 began operating as an institutional private equity firm.

The Lowenstein deal team included Sam E. Khan, Mitchell McDonald, Christopher M. Cozzens, Santino Pelusi, Maxwell Berteletti, Yarissa Subervi, James C. Shehan, Fran Skoller, and Geena M. Caporale.

In the last three years, Lowenstein has represented Hildred Capital Management  and its portfolio companies in such transactions as the acquisition of Hello Bello for $66.8 million; the acquisition of Eclipse MedCorp’s assets; and the acquisition global skincare Company StriVectin®, to name a few.

The deal was reported by The Wall Street Journal.